• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

奥希替尼获得性耐药机制——下一个挑战

Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge.

作者信息

Ríos-Hoyo Alejandro, Moliner Laura, Arriola Edurne

机构信息

Department of Medical Oncology, Hospital del Mar-CIBERONC (Centro de Investigación Biomédica en Red de Oncología), 08003 Barcelona, Spain.

Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), 08003 Barcelona, Spain.

出版信息

Cancers (Basel). 2022 Apr 12;14(8):1931. doi: 10.3390/cancers14081931.

DOI:10.3390/cancers14081931
PMID:35454838
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9027936/
Abstract

EGFR-mutated tumors represent a significant percentage of non-small cell lung cancer. Despite the increasing use of osimertinib, a treatment that has demonstrated an outstanding clinical benefit with a tolerable toxicity profile, EGFR tumors eventually acquire mechanisms of resistance. In the last years, multiple mechanisms of resistance have been identified; however, after progressing on osimertinib, treatment options remain bleak. In this review, we cover the most frequent alterations and potential therapeutic strategies to overcome them.

摘要

表皮生长因子受体（EGFR）突变型肿瘤在非小细胞肺癌中占相当大的比例。尽管奥希替尼的使用越来越广泛，这种治疗方法已显示出显著的临床益处且毒性可耐受，但EGFR肿瘤最终仍会产生耐药机制。在过去几年中，已发现多种耐药机制；然而，在接受奥希替尼治疗病情进展后，治疗选择仍然有限。在本综述中，我们涵盖了最常见的改变以及克服这些改变的潜在治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0813/9027936/3ef622a29ab8/cancers-14-01931-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0813/9027936/3ef622a29ab8/cancers-14-01931-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0813/9027936/3ef622a29ab8/cancers-14-01931-g001.jpg

相似文献

1
Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge.奥希替尼获得性耐药机制——下一个挑战
Cancers (Basel). 2022 Apr 12;14(8):1931. doi: 10.3390/cancers14081931.
2
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.评估 EGFR T790M 阳性肺癌患者对奥希替尼获得性耐药的耐药机制及临床意义。
JAMA Oncol. 2018 Nov 1;4(11):1527-1534. doi: 10.1001/jamaoncol.2018.2969.
3
Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.胰岛素样生长因子-1 受体的激活赋予 EGFR T790M 突变的非小细胞肺癌对奥希替尼的获得性耐药。
Thorac Cancer. 2020 Jan;11(1):140-149. doi: 10.1111/1759-7714.13255. Epub 2019 Nov 22.
4
The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.MEK/ERK/miR-21信号通路在表皮生长因子受体（EGFR）突变的非小细胞肺癌细胞对奥希替尼的耐药中起关键作用。
Cancers (Basel). 2021 Nov 29;13(23):6005. doi: 10.3390/cancers13236005.
5
Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.奥希替尼耐药的非小细胞肺癌患者中 L718V 获得性 EGFR 突变作为机制。
Target Oncol. 2019 Aug;14(4):369-374. doi: 10.1007/s11523-019-00652-6.
6
Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.针对 c-Myc 克服第三代 EGFR 酪氨酸激酶抑制剂奥希替尼治疗 EGFR 突变型 NSCLC 获得性耐药。
Cancer Res. 2021 Sep 15;81(18):4822-4834. doi: 10.1158/0008-5472.CAN-21-0556. Epub 2021 Jul 21.
7
Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.奥希替尼用于表皮生长因子受体（EGFR）T790M突变阳性的非小细胞肺癌
Expert Rev Clin Pharmacol. 2017 Jan;10(1):31-38. doi: 10.1080/17512433.2017.1265446. Epub 2016 Dec 2.
8
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.奥希替尼耐药的 EGFR 突变型肺癌对第一代可逆性 EGFR 抑制剂敏感，但在临床前模型和临床样本中最终会获得 EGFR T790M/C797S 耐药突变。
J Thorac Oncol. 2019 Nov;14(11):1995-2002. doi: 10.1016/j.jtho.2019.07.016. Epub 2019 Aug 1.
9
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.奥希替尼治疗非小细胞肺癌：设计、研发及在治疗中的地位
Lung Cancer (Auckl). 2017 Aug 18;8:109-125. doi: 10.2147/LCTT.S119644. eCollection 2017.
10
Acquired Resistance to Osimertinib in -Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?奥希替尼耐药的 - 突变型非小细胞肺癌：我们如何克服它？
Int J Mol Sci. 2022 Jun 22;23(13):6936. doi: 10.3390/ijms23136936.

引用本文的文献

1
Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature.塞尔帕替尼与奥希替尼联合用于非小细胞肺癌的安全性和有效性：一例病例报告及文献综述
Front Oncol. 2025 May 9;15:1580322. doi: 10.3389/fonc.2025.1580322. eCollection 2025.
2
A novel mesenchymal epithelial transition (MET) inhibitor, CB538, relieves acquired resistance in -mutated -amplified non-small cell lung cancer.一种新型间充质上皮转化（MET）抑制剂CB538可缓解EGFR突变、EGFR扩增的非小细胞肺癌中的获得性耐药。
Transl Cancer Res. 2025 Mar 30;14(3):1915-1927. doi: 10.21037/tcr-24-1614. Epub 2025 Mar 24.
3

本文引用的文献

1
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.同时存在 TP53 突变促进 EGFR 突变型肺腺癌耐药进化。
J Thorac Oncol. 2022 Jun;17(6):779-792. doi: 10.1016/j.jtho.2022.02.011. Epub 2022 Mar 21.
2
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors (KRYSTAL-1).阿达格拉西布（MRTX849）在晚期实体瘤患者中的首次人体 I/IB 期剂量发现研究（KRYSTAL-1）。
J Clin Oncol. 2022 Aug 10;40(23):2530-2538. doi: 10.1200/JCO.21.02752. Epub 2022 Feb 15.
3
EGFR first- and second-generation TKIs-there is still place for them in -mutant NSCLC patients.
Synergistic Anti-Tumor Efficacy Achieved by Reversing Drug Resistance through the Regulation of the Tumor Immune Microenvironment with IL-12 and Osimertinib Combination Therapy.
通过IL-12与奥希替尼联合治疗调节肿瘤免疫微环境逆转耐药性实现协同抗肿瘤疗效。
J Cancer. 2024 Jun 17;15(14):4534-4550. doi: 10.7150/jca.95407. eCollection 2024.
4
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.由染色体不稳定通过p53功能障碍和基因组加倍驱动的靶向治疗的混合反应。
Nat Commun. 2024 Jun 13;15(1):4871. doi: 10.1038/s41467-024-47606-9.
5
Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road.揭示结直肠癌中对抗表皮生长因子受体（EGFR）疗法的获得性耐药：一条漫长而曲折的道路。
Front Pharmacol. 2024 Apr 22;15:1398419. doi: 10.3389/fphar.2024.1398419. eCollection 2024.
6
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.非小细胞肺癌对表皮生长因子受体酪氨酸激酶抑制剂的耐药性：从分子机制到新治疗策略的临床应用
Pharmaceutics. 2023 May 27;15(6):1604. doi: 10.3390/pharmaceutics15061604.
7
The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications.MET在非小细胞肺癌对表皮生长因子受体抑制的耐药中的作用：机制及治疗意义综述
Cancers (Basel). 2023 May 31;15(11):2998. doi: 10.3390/cancers15112998.
8
Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key.联合三种酪氨酸激酶抑制剂：药物监测是关键。
Int J Mol Sci. 2023 Mar 14;24(6):5518. doi: 10.3390/ijms24065518.
9
Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib.克服CEP85L-ROS1、MKRN1-BRAF和MET扩增作为对奥希替尼罕见的获得性耐药突变。
Front Oncol. 2023 Feb 27;13:1124949. doi: 10.3389/fonc.2023.1124949. eCollection 2023.
10
A Case of Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer: Multi-Line Treatment and Resistance Mechanisms.一例表皮生长因子受体突变的非小细胞肺癌病例：多线治疗及耐药机制
Cureus. 2023 Jan 9;15(1):e33577. doi: 10.7759/cureus.33577. eCollection 2023 Jan.
表皮生长因子受体（EGFR）第一代和第二代酪氨酸激酶抑制剂（TKIs）——在EGFR突变的非小细胞肺癌（NSCLC）患者中仍有其用武之地。
Transl Cancer Res. 2019 Jan;8(Suppl 1):S23-S47. doi: 10.21037/tcr.2018.10.06.
4
Targeting HER2 Alterations in Non-Small-Cell Lung Cancer: A Comprehensive Review.针对非小细胞肺癌中HER2改变的综合综述
JCO Precis Oncol. 2020 Nov;4:411-425. doi: 10.1200/PO.19.00333.
5
Divergent - and -Mediated Resistance to Osimertinib in -Mutant NSCLC: A Case Report.EGFR突变型非小细胞肺癌中对奥希替尼的不同介导耐药：一例报告
JCO Precis Oncol. 2021 Nov;5:939-942. doi: 10.1200/PO.21.00083.
6
High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib.在包括奥希替尼在内的接受过EGFR酪氨酸激酶抑制剂长期治疗的患者中，C797S突变的发生率较高。
JTO Clin Res Rep. 2021 May 14;2(7):100191. doi: 10.1016/j.jtocrr.2021.100191. eCollection 2021 Jul.
7
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors.对第三代表皮生长因子受体酪氨酸激酶抑制剂的获得性耐药以及新一代表皮生长因子受体抑制剂的出现。
Innovation (Camb). 2021 Apr 3;2(2):100103. doi: 10.1016/j.xinn.2021.100103. eCollection 2021 May 28.
8
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, -Mutated Non-Small Cell Lung Cancer.Patritumab Deruxtecan（HER3-DXd）在 EGFR 抑制剂耐药、突变型非小细胞肺癌中的疗效和安全性。
Cancer Discov. 2022 Jan;12(1):74-89. doi: 10.1158/2159-8290.CD-21-0715. Epub 2021 Sep 21.
9
Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer.曲妥珠单抗 deruxtecan 治疗 - 突变型非小细胞肺癌。
N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.
10
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.阿美替尼治疗 EGFR 外显子 20 插入突变型非小细胞肺癌：CHRYSALIS Ⅰ期研究的初步结果。
J Clin Oncol. 2021 Oct 20;39(30):3391-3402. doi: 10.1200/JCO.21.00662. Epub 2021 Aug 2.